Catalent Inc (NYSE:CTLT) insider John R. Chiminski sold 181,458 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Catalent Inc (NYSE CTLT) traded down $0.20 during trading on Wednesday, reaching $39.54. The company’s stock had a trading volume of 895,300 shares, compared to its average volume of 909,483. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $5,279.84, a P/E ratio of 27.79, a PEG ratio of 2.55 and a beta of 1.41. Catalent Inc has a 1 year low of $25.08 and a 1 year high of $43.39.

Catalent (NYSE:CTLT) last posted its earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The business’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period last year, the company earned $0.16 earnings per share. equities research analysts forecast that Catalent Inc will post 1.46 EPS for the current year.

Several analysts recently weighed in on CTLT shares. Bank of America restated a “buy” rating and set a $40.00 price objective (up from $38.00) on shares of Catalent in a research report on Tuesday, August 29th. BidaskClub upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Friday, September 8th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, September 7th. J P Morgan Chase & Co restated a “buy” rating and set a $40.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $45.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Catalent presently has an average rating of “Buy” and an average price target of $44.44.

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in shares of Catalent by 15.2% in the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after buying an additional 2,316,849 shares during the period. Vanguard Group Inc. increased its stake in shares of Catalent by 3.8% in the second quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock valued at $355,192,000 after buying an additional 369,526 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Catalent in the second quarter valued at about $239,629,000. JPMorgan Chase & Co. increased its stake in shares of Catalent by 4.6% in the second quarter. JPMorgan Chase & Co. now owns 5,139,690 shares of the company’s stock valued at $180,403,000 after buying an additional 226,705 shares during the period. Finally, State Street Corp increased its stake in shares of Catalent by 10.7% in the second quarter. State Street Corp now owns 4,315,841 shares of the company’s stock valued at $151,488,000 after buying an additional 418,196 shares during the period. Hedge funds and other institutional investors own 99.49% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/13/insider-selling-catalent-inc-ctlt-insider-sells-181458-shares-of-stock.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.